Dry and Wet Age-Related Macular Degeneration | TreatmentTrends | EU | 2014
“TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2014 (EU)” is the third annual syndicated report that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and competitive landscape through comprehensive primary research with retinal specialists across the major European markets (EU5; France, Germany, Italy, Spain, and the United Kingdom). The report covers the current and anticipated use of intravitreal injections, in particular the anti-vascular endothelial growth factor (VEGF) agents (i.e., Roche’s Avastin [bevacizumab], Bayer HealthCare’s Eylea [aflibercept], and Novartis’s Lucentis [ranibizumab]), in the treatment of wet AMD, as well as surveyed retinal specialists’ perceptions of these products—e.g., their advantages and disadvantages, ideal patient types, barriers to growth, and promotional activity. Respondents are also queried on their interest in and willingness to prescribe biosimilar bevacizumab and biosimilar ranibizumab for wet AMD and their awareness of and anticipated use of therapies in development for dry and wet AMD.
